


### **Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

### **In the Claims:**

What is claimed is:

1. (Currently amended) A compound of formula (I) :



wherein:

n is 0, 1, or 2;

t is 0 or 1;

X is  $\text{-NH-}$ ,  $\text{-O-}$ ,  $\text{-R}^{10}\text{-}$ ,  $\text{-R}^{10}\text{O-}$ ,  $\text{-R}^{10}\text{OR}^{10}\text{-}$ ,  $\text{-NR}^{10}\text{-}$ ,  $\text{-R}^{10}\text{N-}$ ,  $\text{-R}^{10}\text{NR}^{10}\text{-}$ ,  $\text{-R}^{10}\text{S(O)}_m\text{-}$ , or  $\text{-R}^{10}\text{S(O)}_m\text{R}^{10}\text{-}$ ;

Y is  $\text{-C(O)-}$  or  $\text{-S(O)}_m\text{-}$ ;

each R is the same or different and is independently selected from the group consisting of

halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,  $\text{-R}^{10}\text{cycloalkyl}$ ,  $\text{Ay}$ ,  $\text{-NHR}^{10}\text{Ay}$ ,  $\text{Het}$ ,  $\text{-NHHet}$ ,  $\text{-NHR}^{10}\text{Het}$ ,  $\text{-OR}^2$ ,  $\text{-OAY}$ ,  $\text{-OHet}$ ,  $\text{-R}^{10}\text{OR}^2$ ,  $\text{-NR}^2\text{R}^3$ ,  $\text{-NR}^2\text{Ay}$ ,  $\text{-R}^{10}\text{NR}^2\text{R}^3$ ,  $\text{-R}^{10}\text{NR}^2\text{Ay}$ ,  $\text{-R}^{10}\text{C(O)R}^2$ ,  $\text{-C(O)R}^2$ ,  $\text{-CO}_2\text{R}^2$ ,  $\text{-R}^{10}\text{CO}_2\text{R}^2$ ,  $\text{-C(O)NR}^2\text{R}^3$ ,  $\text{-C(O)Ay}$ ,  $\text{-C(O)NR}^2\text{Ay}$ ,  $\text{-C(O)Het}$ ,  $\text{-C(O)NHR}^{10}\text{Het}$ ,  $\text{-R}^{10}\text{C(O)NR}^2\text{R}^3$ ,  $\text{-C(S)NR}^2\text{R}^3$ ,  $\text{-R}^{10}\text{C(S)NR}^2\text{R}^3$ ,  $\text{-R}^{10}\text{NHC(NH)NR}^2\text{R}^3$ ,  $\text{-C(NH)NR}^2\text{R}^3$ ,  $\text{-R}^{10}\text{C(NH)NR}^2\text{R}^3$ ,  $\text{-S(O)}_2\text{NR}^2\text{R}^3$ ,  $\text{-S(O)}_2\text{NR}^2\text{Ay}$ ,  $\text{-R}^{10}\text{SO}_2\text{NHCOR}^2$ ,  $\text{-R}^{10}\text{SO}_2\text{NR}^2\text{R}^3$ ,  $\text{-R}^{10}\text{SO}_2\text{R}^2$ ,  $\text{-S(O)}_m\text{R}^2$ ,  $\text{-S(O)}_m\text{Ay}$ , cyano, nitro, or azido;

each  $\text{R}^1$  is the same or different and is independently selected from the group

consisting of halogen, haloalkyl, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,  $\text{-R}^{10}\text{cycloalkyl}$ ,  $\text{Ay}$ ,  $\text{-NHR}^{10}\text{Ay}$ ,  $\text{Het}$ ,  $\text{-NHHet}$ ,  $\text{-NHR}^{10}\text{Het}$ ,  $\text{-OR}^2$ ,  $\text{-OAY}$ ,  $\text{-OHet}$ ,

$-R^{10}OR^2$ ,  $-NR^2R^3$ ,  $-NR^2Ay$ ,  $-R^{10}NR^2R^3$ ,  $-R^{10}NR^2Ay$ ,  $-R^{10}C(O)R^2$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ ,  
 $-R^{10}CO_2R^2$ ,  $-C(O)NR^2R^3$ ,  $-C(O)Ay$ ,  $-C(O)NR^2Ay$ ,  $-C(O)Het$ ,  $-C(O)NHR^{10}Het$ ,  
 $-R^{10}C(O)NR^2R^3$ ,  $-C(S)NR^2R^3$ ,  $-R^{10}C(S)NR^2R^3$ ,  $-R^{10}NHC(NH)NR^2R^3$ ,  
 $-C(NH)NR^2R^3$ ,  $-R^{10}C(NH)NR^2R^3$ ,  $-S(O)_2NR^2R^3$ ,  $-S(O)_2NR^2Ay$ ,  $-R^{10}SO_2NHCOR^2$ ,  
 $-R^{10}SO_2NR^2R^3$ ,  $-R^{10}SO_2R^2$ ,  $-S(O)_mR^2$ ,  $-S(O)_mAy$ , cyano, nitro, or azido;

each m independently is 0, 1, or 2;

each  $R^{10}$  is the same or different and is independently selected from alkylene,  
cycloalkylene, alkenylene, cycloalkenylene, and alkynylene;

p and q are each independently selected from 0, 1, 2, 3, 4, or 5;

each of  $R^2$  and  $R^3$  are the same or different and are independently selected from the  
group consisting of H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,  $-R^{10}$ cycloalkyl,  
 $-R^{10}OH$ ,  $-R^{10}(OR^{10})_w$ , and  $-R^{10}NR^4R^5$ ;

w is 1-10;

each of  $R^4$  and  $R^5$  are the same or different and are independently selected from the  
group consisting of alkyl, cycloalkyl, alkenyl, cycloalkenyl, and alkynyl;

Ay represents an aryl group;

Het represents a 5- or 6-membered heterocyclyl or heteroaryl group;


ring A is aryl or heteroaryl;

provided that when the A ring is aryl, t is 0, and Y is  $SO_2$ , then p is not 0; and or a  
~~pharmaceutically acceptable salts, or solvates and physiologically functional derivatives~~  
thereof.

2. (Original) The compound of claim 1 wherein alkyl is  $C_1$ - $C_6$  alkyl, alkoxy is  $C_1$ - $C_6$  alkoxy, haloalkyl is  $C_1$ - $C_6$  haloalkyl, alkylene is  $C_1$ - $C_6$  alkylene, and alkenylene is  $C_1$ - $C_6$  alkenylene.
3. (Original) The compound wherein t is 0 and Y is  $-C(O)-$ .
4. (Original) The compound wherein t is 0 and Y is  $-S(O)_m-$ .
5. (Previously presented) The compound of claim 1 wherein t is 1, Y is  $-C(O)-$ , and X is  $-NH-$ ,  $-O-$ , or  $-R^{10}$ .
6. (Previously presented) The compound of claim 1 wherein t is 1, Y is  $-S(O)_m-$ , and X is  $-NH-$ ,  $-O-$ , or  $-R^{10}$ .

7. (Original) The compound of claim 1 wherein n is 1.
8. (Original) The compound of claim 1 wherein p is 1 or more and R is selected from halogen, alkyl, haloalkyl,  $-OR^2$ ,  $-NR^2R^3$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ , cyano, nitro, or azido.
9. (Original) The compound of claim 8 wherein R is halogen, alkyl, haloalkyl.
10. (Original) The compound of claim 9 wherein R is substituted *para* to the depicted N atom.
11. (Original) The compound of claim 10 wherein R is halogen.
12. (Original) The compound of claim 11 wherein R is Br or Cl.
13. (Original) The compound of claim 1 wherein q is 1 or more and  $R^1$  is selected from halogen, alkyl, haloalkyl,  $-OR^2$ ,  $-NR^2R^3$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ , Ay, Het, cyano, nitro, or azido.
14. (Original) The compound of claim 13 wherein  $R^1$  is selected from halogen, alkyl, haloalkyl,  $-OR^2$ ,  $-NR^2R^3$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ , or cyano.
15. (Original) The compound of claim 14 wherein  $R^2$  and  $R^3$  each are  $C_1$ - $C_6$  alkyl.
16. (Original) The compound of claim 14 wherein  $R^1$  is selected from halogen, alkyl, or  $-OR^2$ .
17. (Original) The compound of claim 16 wherein said halogen is fluoro or chloro, said alkyl is methyl, and said  $-OR^2$  is alkoxy.
18. (Original) The compound of claim 1 wherein the A ring is aryl.
19. (Original) The compound of claim 18 wherein the A ring is phenyl.
20. (Original) The compound of claim 19 wherein q is 1 or more and  $R^1$  is selected from halogen, alkyl, haloalkyl,  $-OR^2$ ,  $-NR^2R^3$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ , Ay, Het, cyano, nitro, or azido.
21. (Original) The compound of claim 20 wherein q is 1 or more and  $R^1$  is selected from halogen, alkyl, haloalkyl,  $-OR^2$ ,  $-NR^2R^3$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ , or cyano.
22. (Original) The compound of claim 1 wherein the A ring is heteroaryl.
23. (Original) The compound of claim 22 wherein the heteroaryl is pyridyl.
24. (Original) The compound of claim 23 wherein q is 0 or 1.

25. (Currently amended) The compound of claim 24 wherein when q is 1, then  $R^1$  is selected from halogen, alkyl, haloalkyl,  $-OR^2$ ,  $-NR^2R^3$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ , Aryl, Het, cyano, nitro, or azido.
26. (Original) The compound of claim 25 wherein when q is 1, then  $R^1$  is selected from halogen, alkyl, haloalkyl,  $-OR^2$ ,  $-NR^2R^3$ ,  $-C(O)R^2$ ,  $-CO_2R^2$ , or cyano.
27. (Original) The compound of claim 1 wherein p is 1, R is halogen, n is 1, Y is  $-C(O)-$ , t is 0, ring A is heteroaryl, and q is 0.
28. (Original) The compound of claim 27 wherein R is chloro and ring A is pyridyl.
29. (Original) A compound selected from:



30. (Original) The compound of claim 1 selected from  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N*-phenylurea;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N*-(4-methoxyphenyl)urea;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N*-(4-methoxy-2-methylphenyl)urea;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N*-(3-chloro-4-methoxyphenyl)urea;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N*-[4-(dimethylamino)phenyl]urea;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;  
*N*-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;  
*N*-[(1*S*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-phenylacetamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylpropanamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylprop-2-enamide;  
Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-dichlorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-(trifluoromethyl)benzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methoxybenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-nitrobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-chlorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methylbenzamide;  
*N*-(2,3,4,9-Tetrahydro-1*H*-carbazol-1-yl)benzamide;  
*N*-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;

*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;  
*N*-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)nicotinamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)isonicotinamide;  
*N*-Phenyl-*N'*-(2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)urea;  
*N*-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-phenylurea;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-phenylurea;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;  
*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;  
*N*-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;  
*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;  
*N*-[(1*S*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-imidazole-5-carboxamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-pyrazole-5-carboxamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1-methyl-1*H*-pyrazole-3-carboxamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-imidazole-4-carboxamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-pyrazole-3-carboxamide;  
*N*-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide;  
*N*-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide; and  
*N*-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzenesulfonamide.


31. (Original) The compound of claim 1 selected from  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-*N'*-[4-(dimethylamino)phenyl]urea;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;  
*N*-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-phenylprop-2-enamide;  
Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-(trifluoromethyl)benzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-methylbenzamide;  
*N*-(6-Methyl-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;  
*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)nicotinamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)isonicotinamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;  
*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;  
*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-imidazole-4-carboxamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-1*H*-pyrazole-3-carboxamide;

*N*-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide;  
*N*-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide; and  
*N*-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzenesulfonamide.

32. (Original) The compound of claim 1 selected from  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;  
*N*-[(1*R*)-6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;  
Benzyl 6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-ylcarbamate;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-fluorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methoxybenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-nitrobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-chlorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-fluorobenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methoxybenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-3-methylbenzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;  
*N*-(6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)benzamide;  
*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]benzamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-4-methylbenzenesulfonamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)pyridine-2-carboxamide;  
*N*-(6-Bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-6-chloronicotinamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-pyridinecarboxamide;  
*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]pyridine-2-carboxamide;  
*N*-(6-Chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzamide;  
*N*-[(1*R*)-6-chloro-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl]-2-fluorobenzamide;  
*N*-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2,6-difluorobenzamide; and  
*N*-(6-bromo-2,3,4,9-tetrahydro-1*H*-carbazol-1-yl)-2-fluorobenzenesulfonamide.



33. (Currently amended) The A compound of formula (I) according to claim 1  
~~further comprising:~~



~~including salts, solvates and pharmaceutically functional derivatives,~~

wherein  $R^6$  is H, alkyl,  $-OR^2$ ,  $-NR^2R^3$ , Ay, Het,  $-C(O)R^2$ ,  $-CO_2R^2$ ,  $-CONR^2R^3$ ,  $-S(O)_mR^2$ , or oxo, where  $R^2$ ,  $R^3$ , m, Ay, and Het are as defined; and

$R^7$  is H or alkyl;

provided  $R^6$  and  $R^7$  are not both H,

or a pharmaceutically acceptable salt or solvate thereof.

34. (Cancelled).

35. (Previously presented) A pharmaceutical composition comprising a compound according to claims 1 to 33, and a pharmaceutically acceptable carrier.

- 36 – 44 (Cancelled).

45. (Currently amended) A method for the treatment ~~or prophylaxis of~~  
~~oncogenic viruses, including adenoviruses, retroviruses, and of a papovavirus~~  
~~infection family, including polyoma viruses infection~~ and papilloma viruses  
infection comprising ~~the administration~~ administering to a subject in need thereof  
of a therapeutically effective amount of a compound according to any one of  
~~claims claim 1 to 33.~~

46. (Currently amended) A method for the treatment ~~or prophylaxis of~~  
conditions or disorders due to HPV infection comprising ~~the administration of~~  
administering to a subject in need thereof of a therapeutically effective amount of  
a compound according to ~~any one of claims claim 1 to 33.~~

47. (Original) The method of claim 46 wherein the condition or disorder is warts,  
genital warts, cervical dysplasia, recurrent respiratory papillomatosis, or cancers  
associated with papillomavirus infection.